Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related

Read the full 260 word article

User Sign In